| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID4043: Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease |
|
Medicine details |
|
| Medicine name | lecanemab |
| Formulation | intravenous infusion |
| Reference number | 5232 |
| Indication | Treatment for Alzheimer's disease (early) |
| Company | Eisai Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | |